Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061854 · ClinicalTrials.gov registry record · Phase 2

Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 2 study, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase

NCT00061854: Completed Phase 2 study, sponsored by Daiichi Sankyo.

NCT00061854 is a Phase 2 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061854, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have progressive locally advanced or metastatic non-small cell lung cancer.

Interventions

  • DRUG soblidotin

Trial Details

FieldValue
Start Date 2003-04
Est. Completion 2005-05
Phase Phase 2
Daiichi Sankyo

236 total trials

What the finished NCT00061854 record still lists

NCT00061854 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which soblidotin is the first listed.

NCT00061854 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00061854 about?

NCT00061854 is a clinical study titled "Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have progressive locally advanced or metastatic non-small cell lung ca...

What is the current status of trial NCT00061854?

This trial is currently completed. It is a Phase 2 study. The study started on 2003-04. Estimated completion is 2005-05.

What interventions are being tested in trial NCT00061854?

The interventions under investigation include: soblidotin (DRUG).

Who is sponsoring clinical trial NCT00061854?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00061854, the US trial registry maintained by the National Library of Medicine. NCT00061854 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.